The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, presented the latest ...
Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia (>40%) that greatly impair patients’ quality of life. Six recent phase 3 ...
More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
ESMO Congress 2024 Presentation (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial Han B., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback